Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment.
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium.
This article summarizes the milestones in the development of talazoparib leading to its first approval for the treatment of adults with deleterious or suspected deleterious germlineBRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.
Authors: Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA Abstract The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in ear...
ConclusionsTaken together, these results suggest that heterogeneity and subclonal architecture influence the response to targeted treatment in combination with chemotherapy, with possible implications for clinical decision-making and monitoring of treatment efficacy.Trial registrationNCT00773695. Registered 15 October 2008
Conditions: Breast Cancer; Neoplasm, Breast; Breast Diseases Interventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Docetaxel; Drug: Carboplatin; Drug: Placebo Oral Tablet Sponsor: Zhejiang Cancer Hospital Not yet recruiting
Condition: Breast Cancer Intervention: Other: Prosigna PAM-50 assay Sponsors: Dana-Farber Cancer Institute; NanoString Technologies Not yet recruiting